^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:tamoxifen (Estrogen receptor antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Breast Cancer: HER2-Negative and Postmenopausal or Premenopausal Receiving Ovarian Ablation or Suppression…Preferred Regimens…First-Line Therapy...Selective estrogen receptors modulator (tamoxifen or toremifene)...
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer

    Excerpt:
    ...• Women 16 years of age and above• New diagnosed histologically confirmed breast cancer• Premenopausal as defined by the following criteria: o gonadotrophin levels (luteinizing hormone and follicle stimulating hormone) and oestradiol levels within the local laboratory’s reference range for premenopausal females• Ability to provide menstrual cycle information• ER positive (Allred ≥3)• PgR positive (Allred ≥3)• HER2 negative (IHC 1+ or 2+ and HER2/CEP17 ratio of cceptable methods of contraception.b. ...
    Trial ID:
    2017-001521-41
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer

    Excerpt:
    ...ER ≥60% and PR≥60%) on primary tumour at diagnosis/on biopsy of metastasis Histological confirmation of HER2 negative breast cancer on primary tumour at diagnosis/on biopsy of a metastasis The disease-free time of relapsed patients is more than 12 months Once received standard hormone treatment and progressed Clinical or histological confirmation of metastatic or locally advanced disease...
    Trial ID:
    NCT03045653
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Concordance of the IHC4 Score Performed in Local or Central Laboratory to Endopredict in ER+/HER2- Breast Cancer

    Excerpt:
    ...HER2-negative tumor by IHC (score 0 or 1+) and/or fluorescent in situ hybridization (FISH)/chromogenic in situ hybridization (CISH) negative (local assessment) 5....
    Trial ID:
    GEFPICS IHC4
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Evaluation of Endocrine Therapy Effects of Host Immunity in Early Stage Breast Cancer

    Excerpt:
    ...- HER2 negative status is determined by:...
    Trial ID:
    NCT03719495
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

    Excerpt:
    ...- Estrogen receptor (ER)-/ or Progesterone receptor (PR)- positive and HER2-negative...
    Trial ID:
    NCT05878314
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer

    Excerpt:
    ...- Female patients with a first primary diagnosis of hormone receptor-positive, HER2- negative unilateral early breast cancer for whom an endocrine treatment is indicated...
    Trial ID:
    CLEAR-B
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Clinical Trial to Evaluate the Safety and Effectiveness of GDC-0032 When Given Alongside Tamoxifen

    Excerpt:
    ...- Premenopausal and postmenopausal female breast cancer patient with histological proven ER and/or PR positive*, HER2 negative breast cancer (based on the most recent assessment of ER and PR status from primary breast cancer or from recurrent or metastatic disease)....
    Trial ID:
    Poseidon
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

    Excerpt:
    ...- 18 40 mIU/mL and estradiol 10% by IHC) and HER2-negative status (IHC 0 or 1+ or 2+ and FISH negative) on the last biopsy or surgical specimen available....
    Trial ID:
    OLYMPE